CRD initially partnered with Form Bio to improve a DMD therapeutic candidate that was not yet optimized for manufacturing or reduced immunogenicity. Using long-read sequencing, genome integrity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback